Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD19 UCAR-NK cells (0413bf)
- Development stage
- Unknown
- Lead developer
- People's Liberation Army
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-CD19 UCAR-NK cells (Universal CAR-NK cells) is an investigational allogeneic (off-the-shelf) cell therapy consisting of natural killer (NK) cells engineered with a chimeric antigen receptor (CAR) to target the CD19 antigen. Developed by the 920th Hospital of Joint Logistics Support Force of the People's Liberation Army of China, this therapy is designed to treat B-cell hematologic malignancies, including B-cell lymphoblastic leukemia and B-cell lymphoma. Unlike autologous CAR therapies, UCAR-NK cells are derived from healthy donors, allowing for immediate availability. In clinical trial NCT05654038, the cells are administered 1–7 days after hematopoietic stem cell transplantation (HSCT) to leverage the dual anti-tumor and anti-infection effects of NK cells, which may promote stem cell engraftment and improve disease control.
- Other names
- anti-CD19 universal CAR-NK cellsanti-CD-19 universal CAR-NK cellsanti-CD 19 universal CAR-NK cellsanti-CD19 UCAR-NKanti-CD-19 UCAR-NKanti-CD 19 UCAR-NK
02
Targets
Beyond the preview
Go deeper on anti-CD19 UCAR-NK cells (0413bf).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD19 UCAR-NK cells (0413bf).